| 000 | 01728 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514020518.0 | ||
| 264 | 0 | _c20020215 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a1522-1059 | ||
| 024 | 7 |
_a10.1208/ps020329 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVeenstra, D L | |
| 245 | 0 | 0 |
_aAssessing the cost-effectiveness of pharmacogenomics. _h[electronic resource] |
| 260 |
_bAAPS pharmSci _c2000 |
||
| 300 |
_aE29 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xtherapeutic use |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aCarrier Proteins _xgenetics |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aCholesterol Ester Transfer Proteins |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDrug Therapy _xeconomics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aGlycoproteins |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xtherapeutic use |
| 650 | 0 | 4 |
_aMercaptopurine _xtherapeutic use |
| 650 | 0 | 4 |
_aMethyltransferases _xdeficiency |
| 650 | 0 | 4 |
_aPharmacogenetics _xeconomics |
| 650 | 0 | 4 |
_aPharmacology, Clinical _xeconomics |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPravastatin _xtherapeutic use |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 |
_aWarfarin _xpharmacokinetics |
| 700 | 1 | _aHigashi, M K | |
| 700 | 1 | _aPhillips, K A | |
| 773 | 0 |
_tAAPS pharmSci _gvol. 2 _gno. 3 _gp. E29 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1208/ps020329 _zAvailable from publisher's website |
| 999 |
_c11654465 _d11654465 |
||